Also known as dri-foxo4, foxo4 d-retro-inverso · Wikipedia
FOXO4-DRI is a 35-amino-acid D-retro-inverso peptide designed as a senolytic that selectively eliminates senescent cells. It targets the FOXO4-p53 interaction that shields senescent cells from apoptosis, freeing p53 to trigger their selective death while sparing healthy tissue. First described by Baar et al. (Cell, 2017) in aged and chemotherapy-treated mice, FOXO4-DRI has never been tested in humans and exists only as a research tool in the longevity space. All available efficacy and safety data come from rodent and in vitro models, and no human pharmacokinetic data exist.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
FOXO4-DRI is a 35-residue D-retro-inverso peptide derived from a FOXO4 sequence that competitively disrupts the FOXO4-p53 interaction inside senescent cells. In senescent cells FOXO4 sequesters p53 in nuclear bodies, blocking p53-mediated apoptosis; displacing p53 from FOXO4 allows it to translocate to mitochondria and trigger selective senolysis.
Pharmacokinetic properties
Half-life
Not published in humans; rodent studies used intermittent dosing (typically every other day x 3) suggesting effective tissue residence of hours to a day
Routes
intravenous · intraperitoneal · subcutaneous
Bioavailability
Original mouse studies used IV/IP administration. No oral bioavailability. Subcutaneous use is common in the gray-market community but not validated.
Amino-acid sequence
D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro
Use & research dosing
No human dose has ever been established. Original Baar et al. mouse work used ~5 mg/kg IV or IP three times per week for several cycles. In gray-market self-experimentation, protocols of 5-10 mg subcutaneous every other day x 3 doses repeated quarterly are sometimes reported but lack any pharmacokinetic, efficacy, or safety validation in humans. Research framing only — no clinical dose recommendation.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Current state: FOXO4-DRI remains a research-only compound with no IND, no clinical trial registration, and no human pharmacokinetic or safety data. The original 2017 Cell paper drove enormous interest in the longevity community, but follow-up work has stayed in vitro and rodent senescence models. Self-experimentation reports should be treated with extreme skepticism; the compound is one of the least-characterized senolytics in actual human use.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.